Grissinger Michael
SEC insider (Form 3/4/5 filer). CIK 0001757601. Director at Lipocine Inc. (LPCN) and 2 other issuers. 5 reported Form 4/5 transactions since Sep 2024; latest on Aug 3, 2026. Located in SALT LAKE CITY, UT.
Companies Grissinger Michael has filed insider reports for
- Lipocine Inc. (LPCN): Director
- Adicet Bio, Inc. (ACET): Director
- Aprea Therapeutics, Inc. (APRE): Director
Grissinger Michael
CIK: 0001757601
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)5 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Aug 3, 2026LPCN
Lipocine Inc.
AwardDirectStock Option (Right to Buy)
2K shares at avg. $2.11- - Jun 21, 2026ACET
Adicet Bio, Inc.
AwardDirectStock Option (Right to Buy)
4.2K shares- - Jun 16, 2026APRE
Aprea Therapeutics, Inc.
AwardDirect3.1K shares- - Jun 5, 2025APRE
Aprea Therapeutics, Inc.
AwardDirect1K shares- - Apr 17, 2025ACET
Adicet Bio, Inc.
AwardDirectStock Option (Right to Buy)
70.2K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 3, 2026 |  LPCN Lipocine Inc. | Award Stock Option (Right to Buy) | 2,000 | $2.11 | - | Direct |
| Jun 21, 2026 |  ACET Adicet Bio, Inc. | Award Stock Option (Right to Buy) | 4,200 | - | - | Direct |
| Jun 16, 2026 |  APRE Aprea Therapeutics, Inc. | Award | 3,135 | - | $0 | Direct |
| Jun 5, 2025 | APRE Aprea Therapeutics, Inc. | Award | 1,045 | - | - | Direct |
| Apr 17, 2025 | ACET Adicet Bio, Inc. | Award Stock Option (Right to Buy) | 70,200 | - | - | Direct |
1-5 of 5 transactions